Network Version
AP20187 Data Sheet
| Product Name: | AP20187 |
 |
|---|---|---|
| CAS No.: | 195514-80-8 | |
| Cat. No.: | HY-13992 | |
| MWt: | 1482.75 | |
| Formula: | C82H107N5O20 | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 57 mg/mL (38.44 mM); Ethanol : 150 mg/mL (101.16 mM; Need ultrasonic) | |
| Mechanisms: | Target: Metabolic Disease | |
| Biological Activity: | ||
| AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions. IC50 & Target: FKBP homodimerizer[1] In Vitro: When LNCaP cells are treated with AP20187 (B/B Homodimerizer) (100 nM), ro-iCaspase-9 levels are significantly reduced, and the smaller processed active caspase-9 becomes apparent[2]. In Vivo: Real-time PCR analysis shows that AP20187 (B/B Homodimerizer) (0.5 mg/kg, 2 mg/kg, or 5 mg/kg) treatment significantly increases the levels of CHOP mRNA in the CNS of PLP/Fv2E-PERK mice at PID12. AP20187 treatment significantly alleviates EAE-induced myelin damage in these mice. AP20187 (B/B Homodimerizer) treatment significantly reduces the number of degenerating axons and increases the density of axons in the demyelinating lesions in the lumbar spinal cord of PLP/Fv2E-PERK mice[2]. | ||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com